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Objective: The clinical features and outcomes of patients undergoing
heart transplantation after a failed Fontan operation are still debated. The
aim of this study was to retrospectively evaluate our experience in 14
patients undergoing heart transplantation after previous Fontan-type op-
erations.
Methods: From 1990 to 2002, 14 patients underwent heart transplan-
tation in our institution after a previous Fontan procedure. The mean
age at the time of the Fontan operation and at transplantation was 7.3
 2.8 and 17.2  6.3 years, respectively. The indication for trans-
plantation was protein-losing enteropathy in 7 patients, arrhythmia with ven-
tricular dysfunction in 5 patients, and heart failure in 2 patients. All patients
received basic immunosuppressive therapy with cyclosporine (INN: ciclosporin)
and azathioprine without induction therapy or maintenance steroids.
Results: Two hospital deaths occurred: one patient died on the fifth postoperative
day of graft failure, and the second died on the 17th postoperative day after an acute
neurologic event. Two patients died later, one 23 months after transplantation of
acute rejection and the other after 90 months of chronic rejection and endocarditis.
One patient underwent successful reintervention 2 years after heart transplantation
for pulmonary vein obstruction. The 10 surviving patients are in New York Heart
Association class I, with a mean follow-up of 64.5  42 months. One of them was
delivered of a healthy baby 5 years after transplantation. Patients with protein-losing
enteropathy reached a normal protein level within a mean of 10 months (range, 6-18
months) after transplantation. Four patients required a temporary administration
(3-6 months) of oral steroid therapy for recurrent rejection episodes. Currently, 7
patients are taking cyclosporine, and 3 are taking cyclosporine and azathioprine. The
actuarial survival at 1, 5, and 10 years was 86%  9%, 77%  12%, and 62% 
17%, respectively.
Conclusion: Heart transplantation is a good option for patients with a failing Fontan
operation. We documented the reversibility of protein-losing enteropathy in all
patients. No mortality caused by surgical complications was observed.
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Successful application of the so-called Fontanoperation was accomplished in 1968 and re-ported in 1971.1,2 Fontan and colleagues1,2treated a case of tricuspid atresia by surgicallybypassing the right ventricle to obtain separa-tion of the right and left circulation. Subse-
quently, this type of operation has been used in many other
types of congenital heart diseases when a biventricular
repair could not be performed. A wide variety of techniques
has been developed to connect the venous systemic return to
the pulmonary circulation. Since his first operation, Fontan
and many other authors modified the original technique,3,4
and the direct atrial-pulmonary artery connection become
popular.5-11 However, intermediate and long-term results
showed that the Fontan operation was associated with a high
incidence of supraventricular arrhythmia, circulatory path-
way obstruction, decreased ventricular function, increasing
cyanosis, and protein-losing enteropathy (PLE). Total cavo-
pulmonary artery connection (TCPC) has been introduced
to reduce the incidence of supraventricular arrhythmia. This
procedure involves the construction of a cavopulmonary
anastomosis for the superior vena cava (Glenn) and either
an intra-atrial tunnel12-14 or an extracardiac conduit for the
drainage of the inferior vena cava into the pulmonary ar-
tery.15 The TCPC is currently the method of choice, and it
has been widely applied, even in patients with a previous
atriopulmonary connection, with or without associated ar-
rhythmia surgery.16,17 Still, a considerable number of pa-
tients experience late failure, and in some cases heart trans-
plantation remains the only solution to improve survival and
clinical status. The purpose of this study was to evaluate the
results of our experience with heart transplantation in pa-
tients with failing Fontan operations.
Materials and Methods
Patients
From 1985, 575 heart transplantations have been performed at the
Department of Cardiovascular Surgery of Ospedali Riuniti, Ber-
gamo, Italy. Sixty-one of these patients underwent heart transplan-
tation for congenital heart disease. Of these 61, between April
1990 and July 2002, 14 patients underwent transplantation after a
previous Fontan operation and are the subject of our analysis.
The clinical characteristics of our patient population are de-
tailed in Table 1. Overall, before transplantation, the 14 patients
underwent 36 surgical procedures. Sixteen operations consisted of
pre-Fontan palliative procedures, 14 were Fontan operations, 4
were redo Fontan operations, and 2 were second redo Fontan
operations.
A variety of surgical strategies were used to perform Fontan
operations:
● In 3 patients a conduit was initially implanted between the
right atrium and the right ventricle. Subsequently, in 2 pa-
tients the conduits were replaced twice, and the third patient
underwent conversion to Glenn anastomosis and direct atrio-
pulmonary connection.
● In 8 patients a direct connection between the right atrium and
the pulmonary artery was performed. Subsequently, one pa-
tient was converted to TCPC with a Glenn anastomosis and an
intra-atrial baffle.
● In 3 patients a TCPC was performed with a Glenn anastomo-
sis and an intra-atrial baffle. The procedures were performed
in 2 stages in 2 patients.
The mean age at the time of the Fontan operation was 7.3 years
(range, 3-30 years) and 17.6 years (range, 5.3-33.8 years) at the
time of heart transplantation, with a mean weight of 42.8 kg
(range, 13-90 kg).
Indications for heart transplantation were as follows:
● PLE in 7 patients. Concomitant ventricular dysfunction (ejec-
tion fraction, 30%) was present in only one of these patients.
PLE was diagnosed on average 2.3 years after the Fontan
operation (range, 0-9 years). Patients were listed for heart
transplantation after requiring periodic albumin infusion for at
least 1 year. One patient was receiving parenteral nutrition,
and one was in congestive heart failure and receiving venti-
latory support. At the time of heart transplantation, the mean
serum protein level was 3.86 0.48 mg/dL. The median time
interval between the Fontan operation and heart transplanta-
tion was 6.3 years (range, 2.2-12.6 years). The average time
on the waiting list was 5.5 months.
● Supraventricular arrhythmia in 5 patients. These patients were
listed for heart transplantation after recurrent episodes of
uncontrolled arrhythmia in the face of ventricular dysfunc-
tion, which caused very unfavorable hemodynamic conse-
quences.
● Heart failure caused by ventricular dysfunction in 2 patients.
Both patients needed hospitalization and inotropic medication
when enrolled for heart transplantation.
A pretransplantation cardiac catheterization was performed in 12
patients. It is noteworthy that the 7 patients with PLE had a mean
pulmonary pressure of 14.6  2.5 mm Hg, and no gradient was
detected in any segment of the Fontan connection. Five of the 7
patients with ventricular dysfunction, arrhythmias, or both had a
mean pulmonary pressure of 19.4  3.4 mm Hg. All patients with
failing Fontan operations referred for cardiac transplantation were
listed and underwent heart transplantation.
Surgical Technique
Harvesting the donor heart, we took as much donor conduits as
possible to meet the needs for recipient reconstruction. Implant
strategy was modified according to the variety of the anatomic
situations encountered (different previous palliations and congen-
ital abnormalities). In 2 patients cannulation of the femoral vessels
was performed before sternotomy because of the proximity of the
cardiovascular structure to the undersurface of the sternum; in
these patients dissection proceeded uneventfully without extracor-
poreal circulation. In one patient emergency femorofemoral car-
diopulmonary bypass was instituted because of right atrial hem-
orrhage during sternotomy: bleeding was eventually controlled,
and the patient recovered uneventfully. All heart transplantations
except 2, in which deep hypothermia was needed to control ex-
cessive collateral circulation, were performed under moderate hy-
pothermia (24°C-28°C). After cardiectomy and takedown of the
Glenn shunt, atriopulmonary anastomosis, or both, the pulmonary
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arteries were reconstructed by using different techniques. A
bovine pericardium patch was used in 3 patients, a polytetra-
fluoroethylene patch was used in 2 patients, a recipient redun-
dant right atrial wall was used in 2 patients, and donor pulmo-
nary artery bifurcation tissue was used in 3 patients. Direct
reconstruction of pulmonary artery continuity was easily done
without patch interposition in the remaining 4 patients. Because
patients with failing Fontan operations usually do not have
conspicuous cardiomegaly, we tried to avoid significant weight
mismatch between donors and recipients, particularly when an
extensive reconstruction of the pulmonary arteries was required
or when diffuse pleural adhesions caused by a previous thora-
cotomy were present.
The implantation of the new heart was performed with atrial
anastomoses in 7 patients and with direct caval anastomoses in the
other 7 patients, according to surgeon’s preference and anatomic
suitability (TCPC). No patient had persistent bleeding after the
operation.
TABLE 1. Patient profiles
Patient
no. Sex Diagnosis
Previous operations
(age)
Indication
to TXP
Age at
HTx
Donor
age
Weight
at HTx
Donor
weight
Ischemic
time
(min) TXP outcome
Follow-up
(mo)
1 F Tricuspid atresia,
pulmonary
stenosis
1) Fontan: conduit
RA/RV (14 y)
PLE 29.9 y 16 y 62 70 55 Alive 123
2) Conduit
replacement (20 y)
3) Prosthesis RA/RV
(22 y)
2 M DILV, pulmonary
stenosis
1) Left modified BT
shunt (6 mo)
2) Right modified BT
3) Fontan: RA/PA (8
y), shunt (8 y)
Arrhythmias,
LV
dysfunction
18.5 y 23 y 60 70 51 Death
neurologic
complication
0.53
3 M Tricuspid atresia,
VSDTGA
1) Pulmonary artery
banding (6 mo)
2) Fontan: RA/PA 
VSD enlargement
(3 y)
PLE, LV
dysfunction
(EF 30%)
5.3 y 9 y 18 24 205 Death chronic
rejection
91
4 F Tricuspid atresia,
pulmonary
stenosis
1) Left modified BT
shunt (6 mo)
2) Right modified BT
shunt (6 y)
3) Fontan: RA/PA
(7 y)
Atrial
fibrillation,
Right atrium
thrombosis,
LV
dysfunction
(EF 30%)
17 y 11 y 41 65 276 Death
acute
rejection
23.1
5 F Tricuspid atresia,
restrictive
VSD,
pulmonary
stenosis 
TGA
1) Left mod. BT
shunt (2 y)
2) Fontan: RA/PA 
VSD enlargement
(5 y)
LV dysfunction
(EF 30%),
Arrhythmias
12.2 y 14 y 42 55 175 Alive 91.5
6 F Tricuspid atresia,
VSD
1) PA banding (3 y)
2) Fontan: conduit
RA/RV (6 y)
2) Valved conduit
3) Conduit
replacement (18
y), RA/RV (8 y)
PLE 22.4 y 20 y 54 70 52 Alive 117
7 M DILV, pulmonary
atresia
1) Left BT shunt (6
mo)
PLE 18.6 y 10 y 37 35 205 Alive 32.5
2) Right BT shunt (2
y)
3) Fontan: RA/PA (6
y)
4) Permanent
pacemaker (12 y)
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The donor mean age was 14.2  8.5 years, the mean weight
was 52.1  23.7 kg, and the mean ischemic time was 181  83
minutes.
Immunosuppressive Therapy
According to our standard transplantation protocol, these patients
started their immunosuppressive regimens with cyclosporine and aza-
thioprine. Neither antithymocyte nor antilymphocyte globulin nor
other induction therapies were administered. The rejection episodes
were treated with a 3-day therapy of high-dosage intravenous meth-
ylprednisolone (15 mg · kg1 · d1), followed by an oral course of
prednisone in case of consecutive rejections.
Follow-up Monitoring
After discharge, the patients have been followed with physical
examination, echocardiography, electrocardiography, and blood
testing every 1 to 3 months in the first postoperative year and every
3 to 4 months subsequently. Myocardial biopsy was routinely
performed only in patients aging more than 6 years during the first
postoperative year.
TABLE 1. Continued
Patient
no. Sex Diagnosis
Previous operations
(age)
Indication to
TXP
Age at
HTx
Donor
age
Weight
at HTx
Donor
weight
Ischemic
time (min) TXP outcome
Follow-up
(mo)
8 F Tricuspid atresia,
pulmonary
stenosis
1) Left modified BT
shunt (1 mo)
2) Right modified BT
3) Fontan: RA/PA, (4
y), shunt (2 y)
PLE 16.3 y 12 y 43 48 186 Alive 33
9 F Tricuspid atresia,
pulmonary
stenosis
1) Right BT shunt (3
mo)
2) Fontan: RA/PA (6
y)
3) Right PA
angioplastic (9 y)
LV dysfunction
(EF 26%),
arrhythmias
19.1 y 11 y 47 70 180 Alive 69
10 M DIRV, TAPVD,
mitral atresia
1) TAPVD
correction, Glenn
(10 mo)
2) Conduit IVC/PA (6
y)
Ventricular
dysfunction,
severe heart
failure
6.5 y 6 y 16 25 305 Alive 98
11 M Tricuspid atresia,
pulmonary
stenosis
1) Davidson shunt
(10 mo)
2) Fontan: conduit
3) Glenn  RA/PA
connection (14 y),
RA/RV (10 y)
LV
dysfunction,
atrial
fibrillation,
right
atriamal
thrombosis
27.8 y 31 y 63 70 202 Alive 60
12 M DIRV, VSD 1) PA banding 
Glenn (9 mo)
PLE, heart
failure/intubated
7.1 y 2 y 17 13 200 Death,
graft failure
0.36
2) Conduit IVC/PA (6
y)
13 M Tricuspid atresia,
pulmonary
stenosis, TGA
1) Fontan: RA/PA (18
y)
2) Total
cavopulmonary
3) Permanent
pacemaker
connection (3 y)
PLE 33.8 y 29 y 72 90 193 Alive 12
14 F Tricuspid atresia,
VSDTGA
1) PA banding (3
mo)
LV dysfunction
(EF 14%)
11.6 y 8 y 28 25 300 Alive 9
2) Total
cavopulmonary
connection (3 y)
HTx, Heart transplantation; RA, right atrium, RV, right ventricle; PLE, protein-losing enteropathy; DILV/DIRV, double-inlet left/right ventricle; BT, Blalock-
Taussig; PA, pulmonary artery; LV, left ventricle; VSD, ventricular septal defect; EF, ejection fraction; TGA, transposition of the great arteries; TAPVD, total
anomalous pulmonary venous drainage; IVC, inferior vena cava.
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Results
Early Results
There were 2 perioperative deaths. One patient (7.1 years,
17 kg, ventilated, low cardiac output) underwent an emer-
gency operation, and we were urged to accept an undersized
donor heart (2 years, 13 kg). He required extracorporeal
membrane oxygenation implantation for severe low-output
posttransplantation syndrome and died 5 days later of mul-
tiorgan failure. A second patient died 16 days after heart
transplantation of cardiac arrest subsequent to a prolonged
epileptic attack. The postmortem showed a large cerebral
scar probably caused by an old and unrecognized cerebral
infarct.
Of the 12 survivors, only one patient had inadequate
cardiac output that required high inotropic support for a few
days, and subsequently pancreatitis and cytomegalovirus
and Staphylococcus species infection developed. He even-
tually recovered but underwent pacemaker implantation for
a persistent atrioventricular block. A second patient re-
quired surgical plication of a paretic left diaphragm, and a
third patient underwent successful reoperation 3 weeks after
heart transplantation for acute thrombosis of the superior
vena cava after a transjugular myocardial biopsy.
The intubation time was shorter than 24 hours in the 7
patients who had a remarkably straightforward recovery and
between 2 and 16 days (mean, 6 days) in the remaining 7
patients. Intensive care stay was 2 to 23 days (mean, 6.5 days),
and in-hospital recovery was 19 to 90 days (mean, 35 days).
Late Results
Two patients died after hospital discharge. The first died 23
months after heart transplantation of an episode of sudden
acute rejection of the graft. She had been receiving treat-
ment with cyclosporine and azathioprine, and of the 14
myocardial biopsies performed after heart transplantation,
only 3 showed mild or moderate rejection.
The second death occurred in a patient waiting retrans-
plantation for severe chronic rejection 90 months after the
initial heart transplantation. The patient had been readmitted
to the hospital in multiorgan failure and died of a concom-
itant acute aortic endocarditis.
The 10 remaining patients, with a mean follow-up of
64.5  42 months (range, 9.2-123 months) are actually in
good condition with normal heart function.
Actuarial patient survival, according to Kaplan-Meier
estimates, is 86%  9%, 77%  12%, and 62%  17% at
1, 5, and 10 years, respectively (Figure 1).
Patient 10 (Table 1) underwent a successful operation in
another center for stenosis of the pulmonary veins 2 years
after heart transplantation. Before heart transplantation, at
the age of 10 months, this patient had undergone surgical
correction of a total anomalous pulmonary venous drainage.
Patient 1, a 35-year-old women operated on 3 times for
various Fontan modifications, was delivered of a healthy
baby by means of caesarian section 5.5 years after heart
transplantation.
Figure 1. Actuarial survival after heart transplantation in patients with failing Fontan operations. CL, Confidence
limit.
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In the 6 patients with previous PLE, the protein level
reached a normal value after 6 months in 4 patients and after
18 months in 2 patients (Figure 2). Mean serum protein
levels were as follows during the 68 months of mean fol-
low-up (range, 12-123 months): 3.91  0.42 g/dL at 1
month, 6.26  2.3 g/dL at 6 months, 6.38  1.8 g/dL at 12
months, 7.06  0.61 g/dL at 18 months, and 7.42  0.6
g/dL at the last control.
Only 6 of the 12 early survivors had one or more epi-
sodes of acute rejection (total of 19 episodes), and 4 of them
required, for a limited period of time (3-6 months), an oral
course of prednisone.
Of the 10 late survivors, 7 patients are receiving mono-
therapy with cyclosporine for azathioprine intolerance. Two
patients are taking cyclosporine and azathioprine, and one is
taking cyclosporine and mycophenolate mofetil. The cyclo-
sporine oral dose is, on average, 5 1.6 mg · kg1 · d1. The
mean blood creatinine level of the 10 patients was 1.12 mg/dL.
Discussion
The issue of failing Fontan operations is an ever increasing
burden to univentricular patients. Most of the patients in this
study were operated on in the past, when Fontan operations
were performed at advanced age, and possibly the pro-
longed cyanosis played a role in the ultimate failure of the
operation. Nonetheless, it appears inevitable that in any case
some of the patients undergoing Fontan procedures will
eventually require either mechanical or transplantation re-
placement. PLE is a life-threatening complication after the
Fontan operation, the prevalence of which among the 30-
day survivors ranges from 0% to 25%.18-22 This syndrome
has a very dismal prognosis, either with medical or surgical
treatment, with a reported mortality of 46% to 64%.19,20
Pathophysiology is still debated. Chronic venous congestion
always associated with the Fontan circulation might con-
tribute to the intestinal protein loss. The mechanism should
concern disturbed lymph drainage, increased lymph produc-
tion, or both caused by intestinal congestion. Some sort of
vicious circle on the basis of a chronic inflammatory re-
sponse of the enteric system might be involved and related
to individual factors. Certainly, PLE does not occur in all
patients with increased venous pressure and does occur in
some other patients with a favorable hemodynamic pattern
(ie, a mean right atrial pressure of15 mm Hg). As a matter
of fact, our patients who required heart transplantation for
PLE had a lower mean pulmonary artery pressure than those
who received heart transplantation for ventricular dysfunc-
tion, arrhythmia, or both (14.6 vs 19.4 mm Hg). These data
confirm the difficulty in dealing with this complication and
the amount of uncertainty lingering on the different thera-
peutic options. The medical literature has scant information
about heart transplantation and PLE. A multicenter study23
regarding 10 patients who underwent heart transplantation
for PLE after the Fontan operation with 7 long-term survi-
vors reported that one patient had continuous problems with
PLE despite excellent graft function. In another patient PLE
temporarily improved but recurred after 1 year, despite
normal graft function. Other reports of a few single cases
showed a complete resolution of PLE after heart transplan-
tation.24,25 The reason why PLE did not resolve after heart
transplantation in the 2 cases reported in the multicenter
study remains unknown. More detailed hemodynamic find-
Figure 2. Serum protein level before and after heart transplantation.
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ings other than the simple assessment of good graft func-
tion, such as right-side pressures or evaluation of diastolic
function, could shed more light on this issue. It has also
been postulated that some changes in the enteric system
could become irreversible and therefore no longer respon-
sive to hemodynamic normalization. Luckily, this has not
been our experience, and all 6 patients discharged from the
hospital had normalized serum protein levels within 18
months after heart transplantation. According to this, we are
encouraged in pursuing a strategy of heart transplantation in
the presence of PLE after the Fontan operation provided the
medical therapy and surgical treatment aimed to resolve
specific and well-identified hemodynamics problems has
proved to be inefficacious. If heart transplantation is con-
sidered, we suggest it should be undertaken before nutri-
tional debilitation becomes manifest.
Conversion to TCPC with ablative surgery has been
reported as an effective method to treat refractory atrial
arrhythmia after the Fontan procedure.16,17 In our experi-
ence 14 patients affected by untreatable arrhythmia after
Fontan correction underwent TCPC conversion and ablative
surgery. One patient died early of bronchopneumonia, and
13 had good late results. The 5 patients who underwent
heart transplantation for arrhythmia were definitively a dif-
ferent subset of patients because of the concomitant pres-
ence of ventricular dysfunction. One patient (no. 13) re-
quired heart transplantation because after conversion
elsewhere to TCPC for arrhythmia, PLE developed. Our
opinion is that when arrhythmias are associated to detect-
able ventricular dysfunction, the patients should preferably
listed for heart transplantation.
Overall, compared with our global experience with heart
transplantation, the patient undergoing heart transplantation
after a failed Fontan operation had a lower incidence of
acute rejection episodes despite a reduced immunosuppres-
sive therapy. In the 12 early survivors, the incidence of
acute rejections that needed treatment was 1.58 episodes per
patient compared with 4.6 episodes per patient in our global
heart transplantation experience during a comparable length
of follow-up.26 Currently, 7 patients are receiving cyclo-
sporine monotherapy, and none is taking steroids. This is in
contrast with our global experience, in which steroids had to
be chronically introduced in 15% of the patients because of
repeated rejection episodes. Because of the small number of
patients, it is impossible to demonstrate a lower immuno-
reactivity in this group of patients. However, we would like
to speculate that the low rejection rate could be a conse-
quence of a long disease and repeated previous blood trans-
fusion, plasma transfusion, or both. The presence of previ-
ous surgical operations and a long history of disease has not
been shown to be an incremental risk factor. Heart trans-
plantation in these patients is a long and complex operation
in which the surgical experience in the congenital field
coexisting with the transplantation expertise of the surgical
center might play a fundamental role.
In conclusion, this retrospective analysis is encouraging,
showing that heart transplantation has satisfactory early and
midterm results after a failed Fontan operation. Survivors
have been shown to enjoy a good quality of life. We
documented the reversibility of PLE in all cases, but a
longer follow-up in a bigger number of patients is required
to draw definitive conclusions.
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